MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil.
We report a case of acute myelogenous leukemia (AML) with MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia) gene rearrangement after exposure to tegafur/uracil. Cytogenetic and clinical findings in this patient: t(11;17) (q23;q25), AML-M4 morphology, development of AML within a short latent period after first exposure to tegafur/uracil, and good response to remission induction chemotherapy but short remission duration, have been considered typical features of therapy-related acute myelogenous leukemia (t-AML) after exposure to topoisomerase II-targeting agents. This case report suggests that t-AML may develop after exposure to tegafur/uracil and that MLL gene rearrangement may not necessarily be specific to t-AML after exposure to topoisomerase II-targeting agents.
Fukushima
Toshihiro
T
National Kanazawa Hospital, Japan.
Yoshio
Nobuyuki
N
Noto
Yutaka
Y
Kida
Hiroshi
H
D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D002880:Chromosomes, Human, Pair 11; D002886:Chromosomes, Human, Pair 17; D003110:Colonic Neoplasms / Q000150:complications / Q000188:drug therapy; D015321:Gene Rearrangement; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000235:genetics*; D008297:Male; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000235:genetics; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects*; D059005:Topoisomerase II Inhibitors; D014178:Translocation, Genetic
D000964:Antimetabolites, Antineoplastic; D059005:Topoisomerase II Inhibitors; D005641:Tegafur